Aravive Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aravive stock.
View analyst ratings for Aravive or view top-rated stocks.

Wall Street analysts have given Aravive a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Aravive wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Aravive.

Aravive, Inc. (NASDAQ:ARAV) posted its earnings results on Monday, March, 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.27. The business had revenue of $5.69 million for the quarter.
View Aravive's earnings history.

Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARAV stock has increased by 3.6% and is now trading at $5.17.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued 12-month target prices for Aravive's stock. Their forecasts range from $20.00 to $30.00. On average, they anticipate Aravive's share price to reach $25.20 in the next year. This suggests a possible upside of 387.4% from the stock's current price.
View analysts' price targets for Aravive or view top-rated stocks among Wall Street analysts.

Some companies that are related to Aravive include Seelos Therapeutics (SEEL), XOMA (XOMA), Puma Biotechnology (PBYI), UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), Nature's Sunshine Products (NATR), Fortress Biotech (FBIO), Fulcrum Therapeutics (FULC), Cue Biopharma (CUE), Syros Pharmaceuticals (SYRS), Athenex (ATNX), Spruce Biosciences (SPRB), Sesen Bio (SESN), Nabriva Therapeutics (NBRV) and BeyondSpring (BYSI).
View all of ARAV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX).

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARAV stock can currently be purchased for approximately $5.17.

Aravive has a market capitalization of $101.64 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis.

Aravive employs 16 workers across the globe.

The official website for Aravive is www.aravive.com.

Aravive is headquartered at River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098.

Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]